Lynch is out at ImClone
Executive Summary
ImClone Systems CEO Daniel Lynch resigns Nov. 10 "by mutual agreement with the company's board of directors." He was named CEO in February 2004 after serving in that capacity on an interim basis since April 2003. Lynch joined ImClone in April 2001 as vice president of finance and chief financial officer. While the search for a new CEO is conducted, Exec VP and Chief Scientific Officer Philip Frost will serve as interim CEO. A former Wyeth exec, Frost joined ImClone in February (1"The Pink Sheet" Feb. 21, 2005, In Brief)...
You may also be interested in...
ImClone names chief scientific, medical officers
Former Wyeth VP-Oncology Philip Frost joins ImClone as chief scientific officer, filling a position that has been open since Harlan Waksal left in July 2003. ImClone also named Eric Rowinsky chief medical officer. Rowinsky, previously director of the Cancer Therapy & Research Center's Institute for Drug Development in San Antonio, will have responsibility for the colorectal cancer drug Erbitux (cetuximab)...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.